NTLA - Intellia Therapeutics, Inc.
14.22 0.00 (0.00%)
After hours: 5:55PM EDT
| Previous Close | 14.73 |
| Open | 14.74 |
| Bid | 14.13 x 800 |
| Ask | 15.19 x 900 |
| Day's Range | 14.19 - 14.89 |
| 52 Week Range | 11.03 - 32.95 |
| Volume | 362,243 |
| Avg. Volume | 481,384 |
| Market Cap | 650.009M |
| Beta (3Y Monthly) | 2.65 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.96 |
| Earnings Date | Aug 3, 2017 - Aug 7, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 30.81 |
- Zacks•11 days ago
Glaxo Inks Genome Research Deal With University of California
Glaxo (GSK) signs a five-year collaboration contract with the University of California to build a new laboratory for developing new medicines with the aid of CRISPR technologies.
- Simply Wall St.•15 days ago
How Many Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Did Insiders Buy, In The Last Year?
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
- GlobeNewswire•26 days ago
Intellia Therapeutics to Participate at June Healthcare Investor Conferences
CAMBRIDGE, Mass., May 30, 2019 -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9.
- GlobeNewswire•28 days ago
Intellia Therapeutics Names Laura Sepp-Lorenzino, Ph.D., Chief Scientific Officer
CAMBRIDGE, Mass., May 28, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc., (NTLA) has named Laura Sepp-Lorenzino, Ph.D., as its new executive vice president and chief scientific officer. Dr. Sepp-Lorenzino brings decades of leadership and research and development experience, and joins Intellia to head its drug research organization. Andrew Schiermeier, Ph.D., executive vice president of development and corporate strategy, will continue to lead the drug development organization.
- Insider Monkey•2 months ago
Is Intellia Therapeutics, Inc. (NTLA) A Good Stock To Buy?
"October lived up to its scary reputation—the S&P 500 falling in the month by the largest amount in the last 40 years, the only worse Octobers being '08 and the Crash of '87\. For perspective, there have been only 5 occasions in those 40 years when the S&P 500 declined by greater than 20% from […]
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of NTLA earnings conference call or presentation 2-May-19 12:00pm GMT
Q1 2019 Intellia Therapeutics Inc Earnings Call
- ETF Trends•2 months ago
3 Biotech Sector ETFs Bucked the Risk-Off Trend
While the rest of the markets retreated on a round of risk-off selling in response to President Donald Trump’s threats to raise Chinese tariffs, biotechnology stocks and sector-related exchange traded ...
Motley Fool•2 months agoIntellia Therapeutics, Inc. (NTLA) Q1 2019 Earnings Call Transcript
NTLA earnings call for the period ending March 31, 2019.
- Zacks•2 months ago
Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Lags Revenue Estimates
Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of 7.55% and -14.48%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire•2 months ago
Intellia Therapeutics Announces First Quarter 2019 Financial Results and Company Update
Intellia Therapeutics, Inc. (NTLA), reported operational highlights and financial results for the first quarter ended March 31, 2019. “2019 is off to a productive start in support of our mission to advance genome editing to treat a range of severe and life-threatening diseases. In particular, we presented data at the 22nd Annual Meeting of the American Society of Gene and Cell Therapy showing unprecedented CRISPR-mediated, targeted gene insertion in the liver of non-human primates, achieving normal circulating human levels of protein production,” said Intellia President and Chief Executive Officer John Leonard, M.D. “These achievements highlight Intellia’s leadership in CRISPR/Cas9 genome editing as we advance our pipeline towards the clinic.
- GlobeNewswire•2 months ago
Intellia Therapeutics Presents New In Vivo and Engineered Cell Therapy Data at the 22nd Annual Meeting of the American Society of Gene and Cell Therapy
Intellia Therapeutics, Inc. (NTLA), will present today new data, including the first demonstration of targeted gene insertion with CRISPR/Cas9 in the liver of non-human primates (NHPs), at the 22nd Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), taking place April 29-May 2, 2019, in Washington, D.C. Researchers also will present today new in vitro data from Intellia’s lead engineered cell therapy program in acute myeloid leukemia (AML). Later this week at the 2019 ASGCT meeting, Intellia will present new data from its primary hyperoxaluria (PH1) program.
- GlobeNewswire•2 months ago
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2019 Earnings and Company Update
CAMBRIDGE, Mass., April 25, 2019 -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9.
- GuruFocus.com•2 months ago
One-Size-Fits-All CRISPR Lock Could Catapult the Sector Forward
The three pure-play CRISPR stocks have been on the decline since early 2018. Shares of Intellia Therapeutics (NTLA), Editas Medicine (EDIT) and leader CRISPR Therapeutics (CRSP) have magnified the declines of the broader stock indexes late last year. Warning! GuruFocus has detected 3 Warning Signs with NTLA.
- Zacks•2 months ago
Vertex, CRISPR's Gene Editing Drug Gets FDA's Fast Track Tag
FDA grants a Fast Track designation to Vertex (VRTX) and CRISPR Therapeutics' gene editing candidate, CTX001, for a second indication - transfusion-dependent beta thalassemia.
- GlobeNewswire•2 months ago
Intellia Therapeutics Announces Three Oral Presentations on In Vivo and Engineered Cell Therapy Data at the 22nd Annual Meeting of the American Society of Gene and Cell Therapy
CAMBRIDGE, Mass., April 15, 2019 -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), announced three oral presentations at the 22nd Annual Meeting of the American Society of Gene and.
- Investopedia•3 months ago
These Cannabis and China ETFs are Leading the 2019 Rally
Stock investors seeking even bigger returns than the 2019 bull rally might look at five ETFs that have already gained at least 40% year-to-date, approaching triple the 15% pace of the S&P 500. The winners ...
- Investor's Business Daily•3 months ago
CRISPR Biotech Inks Deal To Use Stem Cells In Gene-Editing Medicine
Editas Medicine signed a collaboration deal with oncology player BlueRock Therapeutics on Wednesday — following in the footsteps of other CRISPR gene-editing companies. Editas stock lifted.
- Simply Wall St.•3 months ago
Some Intellia Therapeutics (NASDAQ:NTLA) Shareholders Have Copped A Big 50% Share Price Drop
Intellia Therapeutics, Inc. (NASDAQ:NTLA) shareholders should be happy to see the share price up 23% in the last month. But that's small comfort given the dismal price performance over theRead More...
- Motley Fool•4 months ago
5 Top Gene-Editing Stocks for 2019
The future of treating disease might be gene editing, and these five stocks have the most promising technologies.
- Reuters•4 months ago
Intellia CEO not involved in Starboard's Bristol-Myers board challenge
Intellia Therapeutics Inc Chief Executive John Leonard, who U.S. drug maker Bristol-Myers Squibb Co said last week was nominated by hedge fund Starboard Value LP to sit on its board, is not affiliated with the effort, an Intellia spokeswoman said on Thursday. Smoter declined to offer an explanation on how Leonard's name was included in Starboard's slate of five directors to challenge Bristol-Myers' board. Starboard declined to comment.
- ETF Trends•4 months ago
A Specialty Biotech ETF Strengthens on Optimism Over CRISPR Advancements
A targeted biotechnology ETF strategy jumped Friday after Editas Medicine (NasdaqGS: EDIT) announced fourth quarter results, revealing its latest progress toward the commercialization of its EDIT-101 drug ...
- GlobeNewswire•4 months ago
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2018 Financial Results
Confirmed improved non-human primate liver editing and protein reduction of greater than 95 percent in transthyretin amyloidosis program; investigational new drug application on.
- Zacks•4 months ago
CRISPR Therapeutics Up as Dosing Starts in Thalassemia Study
CRISPR Therapeutics (CRSP) and partner Vertex start dosing of beta thalassemia patients in an early-stage study evaluating gene editing therapy, CTX001. Initiates enrollment in sickle cell disease study.
- Motley Fool•4 months ago
Better Buy: Editas Medicine vs. Intellia Therapeutics
Which stock wins in a matchup between two leading gene-editing biotechs?
